AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25013089 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PCI with DE
Number of subjects: 591
Study 25013089 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI without DE
Number of subjects: 591
Study 25013089 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection with DE
Number of subjects: 591
Study 25013089 — intervention group
Group type: COMPARATOR
Intervention: Distal protection without DE
Number of subjects: 591
Study 25013089 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PCI
Number of subjects: 591
Study 24511648 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure (Group A)
Number of subjects: 94
Study 24511648 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure (Group B)
Number of subjects: 94
Study 24511648 — intervention group
Group type: COMPARATOR
Intervention: ACE/ARB continued throughout the study period (Group C)
Number of subjects: 94
Study 24511648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR < 60 ml/min (Intervention vs Control)
Number of subjects: 94
Study 24511648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR >= 60 ml/min (Intervention vs Control)
Number of subjects: 94
Study 21700760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal nutritional rehabilitation (health education, oral nutritional supplements, exercise, oral testosterone) for 90 days
Number of subjects: 122
Study 21700760 — intervention group
Group type: COMPARATOR
Intervention: Home health education (control group)
Number of subjects: 122
Study 18347680 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg daily for 6 weeks)
Number of subjects: 40
Study 18347680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mg daily for 6 weeks)
Number of subjects: 40
Study 17135813 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement group (n=207)
Number of subjects: 628
Study 17135813 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-improvement group (n=210)
Number of subjects: 628
Study 17135813 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (n=211)
Number of subjects: 628
Study 12937043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine exposure
Number of subjects: 1
Study 12937043 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate exposure
Number of subjects: 1
Study 12937043 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison infants
Number of subjects: 1
Study 10685535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (3 mg single dose)
Number of subjects: 154
Study 10685535 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin (control)
Number of subjects: 154
Study 9564716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention for 1 year
Number of subjects: 209
Study 10147230 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3174724 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g fructose-1,6-diphosphate (FDP)
Number of subjects: 12
Study 3174724 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g dextrose
Number of subjects: 12
Study 3174724 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 29904824 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly minodronate 50 mg every 4 weeks
Number of subjects: 0
Study 29904824 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate or risedronate
Number of subjects: 0
Study 26779704 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program 'Active and safe with wheeled walkers' for 10 weeks (90 min, twice a week)
Number of subjects: 28
Study 26779704 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 persons)
Number of subjects: 28
Study 24884497 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Pillars Approach
Number of subjects: 360
Study 23175340 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2
Number of subjects: 66
Study 23175340 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐γ
Number of subjects: 66
Study 23175340 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 66
Study 21033156 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol wash (A group)
Number of subjects: 37
Study 21033156 — intervention group
Group type: COMPARATOR
Intervention: Water wash (B group)
Number of subjects: 37
Study 18158496 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health nursing services
Number of subjects: 0
Study 15809565 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline load (BSLN) condition, mean of 2.0 kg per leg
Number of subjects: 14
Study 15809565 — intervention group
Group type: EXPERIMENTAL
Intervention: Load condition with a mean of 2.0 kg per leg, increased moment of inertia (MOI5)
Number of subjects: 14
Study 15809565 — intervention group
Group type: EXPERIMENTAL
Intervention: Load condition with a mean of 2.8 kg per leg, increased total lower-extremity mass (Mass5)
Number of subjects: 14
Study 15809565 — intervention group
Group type: COMPARATOR
Intervention: No load (NL)
Number of subjects: 14
Study 12459670 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pretreatment
Number of subjects: 10
Study 12459670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation
Number of subjects: 10
Study 12459670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyclonine inhalation
Number of subjects: 10
Study 12459670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with Salbutamol pretreatment
Number of subjects: 10
Study 12459670 — intervention group
Group type: COMPARATOR
Intervention: Dyclonine
Number of subjects: 10
Study 8877291 — intervention group
Group type: EXPERIMENTAL
Intervention: NDDG criteria
Number of subjects: 709
Study 8877291 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria
Number of subjects: 709
Study 2679258 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination within the first 7 days of life
Number of subjects: 184
Study 2679258 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination before 9 months
Number of subjects: 184
Study 2679258 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination between 9 months and 2 years
Number of subjects: 184
Study 2679258 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination
Number of subjects: 184
Study 1105502 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of salmefamol given by metered aerosol
Number of subjects: 24
Study 1105502 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24
Study 1105502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adrenaline
Number of subjects: 24
Study 1105502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous atropine
Number of subjects: 24
Study 31826336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (540,000 IU single enteral dose)
Number of subjects: 1078
Study 31826336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 1078
Study 27790824 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF combined with intramyocardial (i.m.) injection of autologous bone marrow-derived cells (BMCs)
Number of subjects: 90
Study 27790824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline only)
Number of subjects: 90
Study 27790824 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF with intracoronary (i.c.) injection of BMCs or serum (placebo)
Number of subjects: 90
Study 27790824 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF with peripheral placebo (saline only)
Number of subjects: 90
Study 25930989 — intervention group
Group type: EXPERIMENTAL
Intervention: luseogliflozin
Number of subjects: 37
Study 25930989 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 23389068 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 68
Study 23389068 — intervention group
Group type: COMPARATOR
Intervention: No TAP block (Control)
Number of subjects: 68
Study 21829466 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2
Number of subjects: 30
Study 21829466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2
Number of subjects: 30
Study 21829466 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 (both doses)
Number of subjects: 30
Study 21829466 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 30
Study 19687084 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated polyglactin 910 absorbable sutures
Number of subjects: 59
Study 19687084 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 59
Study 17382134 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal microscopic varicocelectomy
Number of subjects: 120
Study 17382134 — intervention group
Group type: COMPARATOR
Intervention: Open inguinal varicocelectomy
Number of subjects: 120
Study 17382134 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy
Number of subjects: 120
Study 15017205 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg suppository
Number of subjects: 72
Study 15017205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11801926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:50,000 epinephrine
Number of subjects: 40
Study 11801926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:100,000 epinephrine
Number of subjects: 40
Study 11801926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine
Number of subjects: 40
Study 11801926 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine (control)
Number of subjects: 40
Study 9494422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy with radical systematic lymph node dissection (dissection group, n = 59)
Number of subjects: 115
Study 9494422 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy with lymph node sampling (sampling group, n = 56)
Number of subjects: 115
Study 7919313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 47
Study 7919313 — intervention group
Group type: COMPARATOR
Intervention: Control (non-steroid)
Number of subjects: 47
Study 3210286 — intervention group
Group type: COMPARATOR
Intervention: Bland meal with 1950 mg of aspirin (positive control)
Number of subjects: 12
Study 3210286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicy Mexican meal (30 g of jalapeño peppers)
Number of subjects: 12
Study 3210286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepperoni pizza
Number of subjects: 12
Study 3210286 — intervention group
Group type: COMPARATOR
Intervention: Bland meal of unpeppered steak and french fries (negative control)
Number of subjects: 12
Study 3210286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh jalapeño peppers placed directly into the stomach
Number of subjects: 12
Study 868133 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive treatment (300 mg daily for 24 weeks)
Number of subjects: 0
Study 868133 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculated with 1 × 10^6 tachyzoites of the low virulence NC-Argentina LP1 isolate in sterile phosphate-buffered saline (PBS)
Number of subjects: 48
Study 31485864 — intervention group
Group type: COMPARATOR
Intervention: Mock inoculated with sterile PBS
Number of subjects: 48
Study 27633397 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT-WALK (sitting interrupted with 2min light-intensity walking bouts every 20min)
Number of subjects: 25
Study 27633397 — intervention group
Group type: COMPARATOR
Intervention: SIT-STAND (sitting interrupted with 2min standing bouts every 20min)
Number of subjects: 25
Study 27633397 — intervention group
Group type: COMPARATOR
Intervention: SIT-ONLY (uninterrupted sitting)
Number of subjects: 25
Study 26382173 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAS plus aggressive medical therapy
Number of subjects: 451
Study 26382173 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical therapy alone
Number of subjects: 451
Study 22449201 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3051 (8% ciclopirox)
Number of subjects: 0
Study 22449201 — intervention group
Group type: COMPARATOR
Intervention: MRF (5% amorolfine)
Number of subjects: 0
Study 22367664 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate delivered through a long‐acting transdermal system (MTS) for 3 months
Number of subjects: 17
Study 22367664 — intervention group
Group type: COMPARATOR
Intervention: No-medication condition for 3 months
Number of subjects: 17
Study 19697299 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (8 sessions over 2 months)
Number of subjects: 92
Study 19697299 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no reminiscence therapy)
Number of subjects: 92
Study 17408628 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg every second day)
Number of subjects: 36
Study 17408628 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 36
Study 15823886 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐financed collaboration model
Number of subjects: 0
Study 15823886 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 11970780 — intervention group
Group type: EXPERIMENTAL
Intervention: Outgroup members (black and white)
Number of subjects: 0
Study 11970780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup members (shaded)
Number of subjects: 0
Study 9814478 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal muscle sympathetic nerve activity (MSNA)
Number of subjects: 39
Study 8106694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (recombinant tissue‐type plasminogen activator, urokinase or combination therapy) with heparin, aspirin, and calcium‐channel blocking agent.
Number of subjects: 1001
Study 2520637 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-receptor blockade with 10 mg of chlorpheniramine and 400 mg of cimetidine intravenously before protamine infusion.
Number of subjects: 0
Study 2520637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no histamine-receptor blockade).
Number of subjects: 0
Study 335482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 microgram per day for four weeks
Number of subjects: 0
Study 335482 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 0
Study 30488484 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical peer groups based on patient-sharing in claims data
Number of subjects: 142098
Study 30488484 — intervention group
Group type: COMPARATOR
Intervention: Randomly assigned peer groups
Number of subjects: 142098
Study 30488484 — intervention group
Group type: COMPARATOR
Intervention: Empirical peer groups compared to hospital groups
Number of subjects: 142098
Study 28476096 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Chevron/Akin (PECA)
Number of subjects: 50
Study 28476096 — intervention group
Group type: COMPARATOR
Intervention: Open Scarf/Akin (SA)
Number of subjects: 50
Study 25161168 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention (n = 29)
Number of subjects: 57
Study 25161168 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyles control (n = 28)
Number of subjects: 57
Study 24368464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 130
Study 24368464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22398344 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Hatha yoga intervention
Number of subjects: 0
Study 22398344 — intervention group
Group type: COMPARATOR
Intervention: Light exercise group (control)
Number of subjects: 0
Study 19381522 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone administered via jet nebulizer for 4 hours
Number of subjects: 48
Study 19381522 — intervention group
Group type: COMPARATOR
Intervention: Intravenous milrinone (50 microg/kg bolus, then 0.5 microg/kg/min infusion for 4 hours)
Number of subjects: 48
Study 16847294 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 1384
Study 14722591 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 20
Study 14722591 — intervention group
Group type: COMPARATOR
Intervention: No distraction intervention (control condition)
Number of subjects: 20
Study 10912546 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 4 IU/m2 per day, for a maximum of 8 years
Number of subjects: 45
Study 10912546 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 45
Study 9065965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 0
Study 9065965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8351307 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 36
Study 8351307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3555046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (750 mg twice daily)
Number of subjects: 30
Study 3555046 — intervention group
Group type: COMPARATOR
Intervention: Other antimicrobial therapy
Number of subjects: 30
Study 29749371 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg twice a day)
Number of subjects: 250
Study 29749371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (100 µg in the evening)
Number of subjects: 250
Study 27549387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.3 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with rocuronium 0.9 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.3 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.6 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with rocuronium 0.9 mg/kg
Number of subjects: 368
Study 27549387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 368
Study 27549387 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia
Number of subjects: 368
Study 24252943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 60
Study 24252943 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide
Number of subjects: 60
Study 22472338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin simulation of an adverse event
Number of subjects: 16
Study 22472338 — intervention group
Group type: COMPARATOR
Intervention: Written description of an adverse event
Number of subjects: 16
Study 19967631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea (O)
Number of subjects: 982
Study 19967631 — intervention group
Group type: COMPARATOR
Intervention: Barley tea (B)
Number of subjects: 982
Study 19967631 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (W)
Number of subjects: 982
Study 17920718 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 52 weeks
Number of subjects: 31
Study 16110408 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0
Study 16110408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 16110408 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular targeted therapy (tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors, endothelin receptor antagonists)
Number of subjects: 0
Study 12409680 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (n=843)
Number of subjects: 2027
Study 12409680 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) (n=743)
Number of subjects: 2027
Study 12409680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=441)
Number of subjects: 2027
Study 12409680 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM score
Number of subjects: 2027
Study 10567778 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin, 320 mg p.o. once daily
Number of subjects: 15
Study 10567778 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 7589039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 7589039 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study 2177482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium bicarbonate (HSB) 100 mEq IV over 5 minutes
Number of subjects: 10
Study 2177482 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV over 5 minutes
Number of subjects: 10
Study 44375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400 ‐‐ 2100 mg/day)
Number of subjects: 11
Study 44375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29940565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended first-trimester combined screening (eFTCS) with assessment of nasal bone, tricuspid flow, and ductus venosus flow.
Number of subjects: 688
Study 29940565 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound + cell-free DNA (cfDNA) screening.
Number of subjects: 688
Study 28741675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinalbuphine sebacate (DNS) 150 mg
Number of subjects: 12
Study 28741675 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine HCl 20 mg
Number of subjects: 12
Study 26395825 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based exercise (YE)
Number of subjects: 20